Iteos Therapeutics Stock Analysis

Iteos Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.7. Some equities with similar Price to Book (P/B) outperform the market in the long run. Iteos Therapeutics recorded a loss per share of 3.05. The entity had not issued any dividends in recent years. Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. Iteos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Iteos Therapeutics call Michel Detheux at 339 217 0161 or check out https://www.iteostherapeutics.com.

Iteos Therapeutics Investment Alerts

Iteos Therapeutics Upcoming and Recent Events

Iteos Largest EPS Surprises

View All Earnings Estimates

Iteos Therapeutics Environmental, Social, and Governance (ESG) Scores

Iteos Stock Institutional Investors

Note, although Iteos Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Iteos Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 392.69 M.

Iteos Profitablity

Management Efficiency

Iteos Therapeutics has return on total asset (ROA) of (0.1454) % which means that it has lost $0.1454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2368) %, meaning that it created substantial loss on money invested by shareholders. Iteos Therapeutics' management efficiency ratios could be used to measure how well Iteos Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.26 in 2025. At this time, Iteos Therapeutics' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 186.3 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 4.1 M in 2025.

Technical Drivers

As of the 20th of July, Iteos Therapeutics retains the Risk Adjusted Performance of 0.2374, downside deviation of 2.35, and Market Risk Adjusted Performance of 3.58. Iteos Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Iteos Therapeutics mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Iteos Therapeutics is priced fairly, providing market reflects its last-minute price of 10.26 per share. Given that Iteos Therapeutics has jensen alpha of 0.9747, we strongly advise you to confirm Iteos Therapeutics's regular market performance to make sure the company can sustain itself at a future point.

Iteos Therapeutics Price Movement Analysis

Iteos Therapeutics Insider Trading Activities

Iteos Therapeutics Outstanding Bonds

Iteos Therapeutics Predictive Daily Indicators

Iteos Therapeutics Corporate Filings

Iteos Therapeutics Forecast Models

Iteos Therapeutics' time-series forecasting models are one of many Iteos Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Iteos Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Iteos Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Iteos shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Iteos Therapeutics. By using and applying Iteos Stock analysis, traders can create a robust methodology for identifying Iteos entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Iteos analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Iteos analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Iteos Therapeutics stock analysis indicators help investors evaluate how Iteos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Iteos Therapeutics shares will generate the highest return on investment. By understating and applying Iteos Therapeutics stock analysis, traders can identify Iteos Therapeutics position entry and exit signals to maximize returns.

When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.